Loading clinical trials...
Loading clinical trials...
Lung Cancer Screening With Low-dose CT in China (CLUS Study) Version 3.0
CLUS version 1.0, had proven that LDCT led to a 74.1% increase in detecting early-stage lung cancer compare to usual care (NCT02898441). CLUS version 2.0 evaluated the efficacy of new techniques (AI, AFI and MTB) in fostering the implementation of lung cancer screening (NCT03975504). The present multi-center study is performed to evaluate the effectiveness of different lung cancer screening strategy and validate our previous findings. 100,000 high-risk subjects (age 45-75) were recruited to take LDCT screening (Baseline + 2 biennial repeated LDCT screening). Follow-up for lung cancer incidence, lung cancer mortality and overall mortality was performed. Blood samples were stored in a Biobank. Management of positive screening test was carried out by a pre-specified protocol.
Age
45 - 75 years
Sex
ALL
Healthy Volunteers
Yes
Shanghai Chest hospital
Shanghai, Shanghai Municipality, China
Start Date
January 1, 2022
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
August 9, 2022
100,000
ESTIMATED participants
Whole-process management software
OTHER
LDCT detection
DEVICE
Lead Sponsor
Shanghai Chest Hospital
NCT07190248
NCT07486219
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07485114